drugset / Trial / NCT02403635
Drug-Drug Interaction Study: ASP2151 and Midazolam
NaSingle-groupOpen-labelOther
Summary
CYP3A4 is involved in the metabolism of many drugs. So, it is important to assess in vivo the induction effect of ASP2151 on that enzyme to determine the extent of any possible drug interactions. The aim of this trial is to investigate the potential for interaction of ASP2151 with the CYP3A4 probe substrate midazolam.
Timeline
- Start
- 2015-04
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amenamevir | Small molecule | 400 mg | Oral |
| Subject | Midazolam | Small molecule | 7.5 mg | — |
Indications
No indication recorded.